^
    Apply
    A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases (EBVision) (NCT04554914)
    Phase 2
    Atara Biotherapeutics
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/14/2021
    Primary completion :
    06/01/2027
    Completion :
    05/01/2029
    CD20
    |
    CD20 negative
    |
    Tab-cel (tabelecleucel)
    Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS 2) (NCT04031677)
    Phase 3
    European Organisation for Research and Treatmen...
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    01/20/2021
    Primary completion :
    04/21/2027
    Completion :
    04/21/2028
    MDM2 • CDK4
    |
    MDM2 amplification
    |
    doxorubicin hydrochloride • epirubicin
    Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (NCT05836571)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/05/2024
    Initiation :
    10/25/2023
    Primary completion :
    05/15/2026
    Completion :
    05/15/2026
    TMB • CD68
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
    FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (NCT03926936)
    Phase 2
    Frederic Amant
    Completed
    Last update posted :
    05/27/2024
    Initiation :
    03/13/2019
    Primary completion :
    04/01/2022
    Completion :
    12/27/2022
    ER
    |
    ER positive
    |
    fulvestrant
    Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (NCT02428192)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    04/02/2024
    Initiation :
    04/22/2015
    Primary completion :
    09/20/2018
    Completion :
    03/05/2025
    PD-1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar)
    Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) (NCT03851614)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    04/08/2019
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    HRD • CD4
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    12/31/2019
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Imlygic (talimogene laherparepvec)
    Letrozole in Uterine Leiomyosarcoma (NCT05649956)
    Phase 2
    GOG Foundation
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    03/01/2024
    Primary completion :
    06/30/2028
    Completion :
    06/30/2029
    ER
    |
    letrozole
    A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804)
    Phase 1/2
    OncoResponse, Inc.
    Recruiting
    Last update posted :
    11/02/2023
    Initiation :
    09/09/2021
    Primary completion :
    04/15/2024
    Completion :
    08/15/2024
    EGFR • PD-L1 • BRAF • ALK • NTRK
    |
    EGFR mutation • BRCA mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • Libtayo (cemiplimab-rwlc) • OR2805
    Targeting ATR in Soft-tissue Sarcomas (TARSARC) (NCT04807816)
    Phase 2
    Institut Bergonié
    Recruiting
    Last update posted :
    09/28/2023
    Initiation :
    02/09/2022
    Primary completion :
    10/01/2024
    Completion :
    04/01/2026
    CD8 • CD4
    |
    gemcitabine • berzosertib (M6620)
    Niraparib for the Treatment of Leiomyosarcoma (NCI-2021-12582) (NCT05174455)
    Phase 2
    David Liebner, MD
    Withdrawn
    Last update posted :
    09/18/2023
    Initiation :
    12/01/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1
    |
    BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation
    |
    Zejula (niraparib)